Patent 11859001 was granted and assigned to Synthekine on January, 2024 by the United States Patent and Trademark Office.
The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.